MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer.
N. Portman, H. H. Milioli, S. Alexandrou, R. Coulson, A. Yong, K. J. Fernandez, K. Chia, D. Segara, A. Parker, S. Haupt, Y. Haupt, W. D. Tilley, A. Swarbrick, C. E. Caldon, E. Lim
This study evaluates MDM2 inhibition combined with endocrine therapy and CDK4/6 inhibition in ER-positive breast cancer, showing synergistic anti-tumor effects in resistant models.
bioRxiv · Jun 9, 2020Cancer Biology